Pharmaceutical Supply Chain Resilience in a Shifting Market
Pharma companies are curbing investment amid pricing pressure and growth anxiety, creating a self‑fulfilling slowdown. To protect against supply disruptions, firms are auditing entire supply chains, adding second and third sources, and holding safety stock, which ties up cash. Geographic diversification away from India and China is pursued, but sourcing APIs domestically remains costly and limited. These moves reflect a broader shift toward resilient, risk‑aware supply networks.
Seven Biotech Companies to Know in the Netherlands
The Netherlands hosts a dense biotech ecosystem anchored by hubs such as Leiden Bio Science Park, which supports over 400 firms and 25,000 jobs. Seven standout companies illustrate the country’s breadth, from Leyden Labs’ intranasal antibody sprays to Merus’ bispecific...
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026
Sarepta Therapeutics is shifting focus from a troubled DMD gene‑therapy portfolio to a robust siRNA pipeline partnered with Arrowhead. Jefferies highlights upcoming Phase I/II data for SRP‑1001 (FSHD) and SRP‑1003 (DM1) in Q1 2026, projecting a potential 25‑50% stock move. The...
AI Innovations Transform Glioma Diagnosis and Treatment
Artificial intelligence platforms are now integrating multimodal imaging, genomics, and clinical data to improve glioma diagnosis and personalize treatment plans. Recent trials show AI‑driven segmentation reduces radiologist workload by 40% and predicts tumor grade with 92% accuracy. Companies such as...
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
The U.S. Food and Drug Administration has lifted the partial clinical hold on Merck and Daiichi Sankyo’s antibody‑drug conjugate ifinatamab deruxtecan (I‑DXd) in the Phase III IDeate‑Lung02 trial for relapsed small‑cell lung cancer. The companies can now resume enrollment and data...
Marea Takes Drug for Acromegaly to Phase 2
Marea Therapeutics announced that its experimental drug for acromegaly has entered Phase 2 clinical testing. The move follows CEO Josh Lehrer’s October 2023 appointment and a review that revealed the compound had not met earlier expectations in pre‑clinical models. The Phase 2...
Superorganism Raises $25M to Back Biodiversity Startups
Superorganism, launched in 2023, closed its inaugural fund with $25.9 million from investors including the Cisco Foundation and Andreessen Horowitz partner Jeff Jordan. The firm will write $250,000‑$500,000 checks for pre‑seed and seed‑stage biodiversity startups and donate 10 % of profits to...
Global Autism: Risks, Burden, and Implications Uncovered
A 2026 Pediatric Research study by Saad et al. merges worldwide epidemiological data with molecular profiling to map Autism Spectrum Disorder’s (ASD) prevalence, risk factors, and economic impact. The analysis reveals a global prevalence of roughly 1.2%, with marked regional...
Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront
Novartis has agreed to pay $50 million upfront to license a peptide‑based radiopharmaceutical asset from China’s Zonsen PepLib Biotech. The agreement, announced Monday, adds a novel imaging candidate to Novartis’ growing portfolio of radiopharma programs. Zonsen PepLib, a biotech focused on...
#JPM26: Day 2 at the JP Morgan Healthcare Conference
Amgen announced on day two of the J.P. Morgan Healthcare Conference that its experimental long‑acting obesity injection, Maritide, met primary endpoints in a Phase 2 trial. The data showed statistically significant weight loss and favorable safety signals in patients with obesity....
AbbVie Turbocharges Its US Investment Promise to $100bn
AbbVie has signed a most‑favoured‑nation pricing deal with the Trump administration, committing $100 billion to U.S. research, development and manufacturing over the next ten years. The agreement mirrors those of 16 other large pharma firms and secures an exemption from potential...
Sentynl Gets the First US Approval for Rare Copper Absorption Disease
Sentynl Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its investigational therapy targeting Menkes disease, a rare and fatal genetic disorder of copper absorption. The approved product, branded Zycu..., is the first therapy in the...
Maternal Vitamin K Intake Shapes Early Brain Development
New research shows that maternal vitamin K consumption during pregnancy significantly influences early brain development in offspring. The study, involving longitudinal imaging and cognitive testing of 1,200 infants, found higher maternal K intake associated with increased myelination and better neurocognitive...
JPM: Is the UK's Clinical Trials Sector Turning a Corner?
The UK medicines regulator reported a 9% rise in clinical trial applications year‑over‑year, with early‑stage studies leading the growth. Healthy‑volunteer and first‑in‑human trials increased 16% and 5% respectively, while sponsor requests for regulatory advice surged 75%. The MHRA announced a...
Open-Sourcing the Future of Food: New Cell Bank Makes Cultivated-Meat Tech Public
Tufts University's Center for Cellular Agriculture (TUCCA) and the Good Food Institute have purchased eight cultivated‑beef cell lines and serum‑free media from the defunct SciFi Foods. The assets, including CRISPR‑edited lines capable of indefinite growth in single‑cell suspension, will be...
Lactate Triggers GPR81/FARP1 for Insulin-Free Glucose Uptake
Researchers have identified that extracellular lactate activates the GPR81 receptor, which in turn engages the FARP1 signaling cascade to promote glucose uptake without insulin. The study demonstrated a 30% increase in glucose transport in muscle cells and a 20% boost...
Treg Biotech Sonoma Sheds Staff After Getting New CEO
Sonoma BioTherapeutics, a T‑regulatory cell biotech based in Sonoma, announced a workforce reduction across its Seattle, South San Francisco and remote positions following the appointment of a new chief executive officer. The cuts affect multiple departments as the company seeks...
Merck to Complete Acquisition of Cidara Therapeutics
Merck completed its cash tender offer to acquire Cidara Therapeutics, paying $221.50 per share. The offer was accepted for 27.15 million shares, representing about 86% of Cidara’s outstanding stock, and will be finalized through a merger making Cidara a wholly‑owned subsidiary....
Carvacrol and Chloroquine Synergistically Halt Melanoma Metastasis
Researchers have demonstrated that the natural compound carvacrol and the antimalarial drug chloroquine work synergistically to trigger apoptosis in metastatic melanoma cells. In vitro experiments showed markedly higher cell death when both agents were combined than when used alone, and...
Congress' Biotech Panel Pitches FDA Policy Upgrades to Help Performance
The National Security Commission on Emerging Biotechnology released a report urging the FDA to modernize its policies as biotech innovation outpaces regulation. The document proposes nearly two dozen specific reforms aimed at accelerating approvals while preserving safety. Recommendations include real‑time...
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Big‑pharma leaders including AbbVie, Amgen and Eli Lilly urged the FDA to decouple pre‑approval inspections from marketing applications and modernize its post‑approval change framework. They argue the 1990s SUPAC guidance treats all biologics as high‑risk, slowing domestic facility transfers. The coalition...
At JPM26, Experts Try To Look Past the Most Favored Nation ‘Distraction’
At JPM26, life‑science investors and policymakers dissected the Trump administration’s disruptive biotech agenda. Health Secretary Robert F. Kennedy Jr. ordered the CDC to drop several childhood‑vaccine recommendations, unsettling billion‑dollar vaccine revenues. The administration’s focus on Most Favored Nation (MFN) drug‑pricing leverage spurred a...
JPM Lineup: New Roles Across Industry
Dozens of biotech firms and investors announced senior‑level moves ahead of the J.P. Morgan Healthcare Conference, with several companies naming new CEOs. At Argenx, co‑founder Tim Van Hauwermeiren is stepping down after 18 years to become chairman, while COO Karen Massey, a...
Gamma Rays Quickly Toughen Nitrogen‑fixing Bacteria
Researchers at Japan’s National Institutes for Quantum Science and Technology combined adaptive laboratory evolution with repeated gamma‑ray mutagenesis to create heat‑tolerant Bradyrhizobium diazoefficiens strains. By exposing cultures to stepwise temperature increases and ten 40 Gy irradiation rounds, they reduced development time...
Nine-Digit Venture Rounds for Mirador, Kinaset
Mirador Therapeutics announced a $120 million Series B round, while KinaseT secured $95 million in a Series A financing. Both rounds were led by top‑tier biotech investors including OrbiMed, ARCH Venture Partners and Sofinnova Partners. The capital will accelerate the companies' oncology and immunotherapy...
JPM Day 1: Big Bucks for Bispecific
AbbVie announced a $5.6 billion agreement with RemeGen to acquire rights to a bispecific antibody that simultaneously blocks PD‑1 and VEGF. The deal, disclosed at JPMorgan’s Day 1 event, provides RemeGen with a substantial upfront payment and ties future milestones to clinical...
Trenchant BioSystems Reports Multiple Data Readouts From AutoCell CGT Manufacturing Prototype
Trenchant Biosystems unveiled data from its AutoCell CGT manufacturing prototype, claiming a reduction of vein‑to‑vein timelines from six weeks to just 2.5 days. The platform reportedly delivers a seven‑fold increase in gene‑modified cell yield while cutting costs by up to...
New Early Stage VC Apuri Seeks to Seed China’s Academic Discoveries
Apuri, a new Shanghai‑based early‑stage venture firm, is launching its debut fund to commercialize biotech breakthroughs emerging from China’s academic labs. The firm is founded by three seasoned entrepreneurs whose backgrounds span biotech executive leadership, investment banking and venture capital....
Robotic Nanoprobe Enables Precise Extraction of a Single Mitochondrion From a Living Cell
Researchers at HKUST have unveiled an automated robotic nanoprobe that can locate and extract a single mitochondrion from a living cell without fluorescent labels. The device integrates nanoelectrodes that sense ROS/RNS bursts and dielectrophoretic nanotweezers that capture the organelle within...
Designer Enzyme Enables Yeast to Produce Custom Fatty Acids, Reducing Need for Palm Oil
A team led by Prof. Martin Grininger at Goethe University engineered a fatty‑acid synthase (FAS) enzyme that lets yeast synthesize custom short‑chain fatty acids, demonstrated with a 12‑carbon product normally sourced from palm or coconut oil. By swapping a single...
Pretzel Buys Rome and Its ‘Dark Genome’ Work
Pretzel Therapeutics announced the acquisition of Rome Therapeutics, a company specializing in “dark genome” research. The deal brings Rome’s functional genomics platform, extensive data sets, and scientific team under Pretzel’s AI‑driven drug discovery umbrella. Financial terms were not disclosed, but...
Nvidia-Partnered Startup Reveals AI-Generated Enzymes for Precise Gene Insertion
Basecamp Research, in partnership with Nvidia, unveiled a gene‑editing toolkit built from AI‑generated enzymes. The startup leveraged evolutionary deep‑learning models running on Nvidia GPUs to design proteins that insert DNA sequences with unprecedented precision. Early laboratory data indicate higher on‑target...
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Novo Nordisk CEO Mike Doustad highlighted the explosive growth of telehealth‑driven GLP‑1 obesity drug sales. He noted that compounding pharmacies have rapidly scaled to meet demand, creating a new distribution model. Doustad argued that traditional pharma can learn from this...
Tracking Daily Mobility in Atypical Parkinsonian Patients
Researchers have deployed wearable sensors to continuously monitor daily mobility in patients with atypical Parkinsonian disorders. The study captured granular gait, step count, and activity‑level data over several weeks, revealing distinct movement signatures across disease subtypes. Findings show that reduced...
At FDA's Request, Pfizer Helps Ease Shortage of Potential Autism Drug
The U.S. Department of Health and Human Services confirmed that, at the FDA's request, Pfizer has been enlisted to help alleviate a nationwide shortage of a drug being promoted by Robert F. Kennedy Jr.'s organization as a potential autism treatment....
Compressed Data Technique Enables Pangenomics at Scale
Engineers at UC San Diego introduced PanMAN, a new data structure and compression format for pangenomics. PanMAN stores mutation‑annotated trees in a network, capturing phylogeny, recombination and whole‑genome alignments while representing each mutation only once. The approach achieves up to...
Cross-Species Links: Developmental Origins of Adult Hypersomnia
A new cross‑species study uncovers how early developmental disruptions predispose adults to hypersomnia. Researchers compared mouse, zebrafish, and human data, linking altered orexin signaling and circadian gene expression to chronic sleepiness. The analysis identified three molecular pathways—neuroinflammation, synaptic pruning deficits,...
Gut Dysbiosis Links to Skin Immune Responses in Mice
A recent pre‑clinical study demonstrates that gut dysbiosis in mice drives pronounced skin immune responses, particularly elevating Th17‑mediated inflammation. Researchers induced microbiome imbalance through antibiotics and high‑fat diet, then observed increased skin cytokine levels and histological signs of dermatitis. Fecal...
High-Speed AFM Imaging Reveals How Brain Enzyme Forms a Dodecameric Ring Structure
Scientists at Kanazawa University used high‑speed atomic force microscopy to capture real‑time images of the brain enzyme CaMKII, revealing that its 12‑subunit ring assembles with α and β subunits in a 3:1 ratio. The β subunits preferentially cluster together, forming...
Tjoapack Expands Bottle Packaging at Netherlands Facility
Contract packaging firm Tjoapack announced the addition of an oral solid‑dosage bottle packaging line at its Etten‑Leur, Netherlands site. The Cremer Uhlmann IBC 50 line can fill up to 50 bottles per minute, handling any bottle shape and integrating carton, leaflet and...
Tahoe, Arc Institute, and Biohub Join Forces on Massive Virtual Cell Dataset
Tahoe Therapeutics, the Arc Institute and Biohub have pledged multi‑million‑dollar investments to create the largest virtual‑cell dataset to date, generating more than 120 million single‑cell data points across 225,000 perturbations using Tahoe’s Mosaic technology. The new resource will be over four...
FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study
The U.S. Food and Drug Administration removed a partial clinical hold on the Phase 3 trial jointly run by Merck and Daiichi Sankyo for a lung‑cancer therapy. The hold, originally imposed over safety and data‑integrity concerns, is now lifted, allowing...
Eye for Trouble: Automated Counting for Chromosome Issues Under the Microscope
Researchers at Tokyo Metropolitan University unveiled a machine‑learning suite that automatically detects and counts sister chromatid exchanges (SCE) in microscope images. The system integrates chromosome identification, SCE classification, and clustering, achieving an overall accuracy of 84.1 %. Validation on cells lacking...
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
Eisai announced a licensing agreement with Nuvation Bio to develop a novel lung‑cancer pill, securing exclusive rights and an upfront cash payment plus milestone fees. The deal positions Eisai to expand its oncology portfolio amid competitive immunotherapy markets. Meanwhile, Alnylam...
Jubilant Biosys Announces New Facility in India
Jubilant Biosys Limited announced the opening of a new discovery and pre‑clinical facility in Noida, India, that doubles its chemistry capacity and integrates early‑phase scale‑up with R&D labs. The 20,000‑sq‑ft campus adds fifteen reactors, two pilot‑plant blocks, and expands the...
AbbVie Jumps Into PD-1xVEGF Bispecific Race, Pays $650M Upfront to RemeGen
AbbVie announced a $650 million upfront deal with Chinese biotech RemeGen to acquire a bispecific antibody that simultaneously blocks PD‑1 and VEGF, marking its entry into the fast‑growing PD‑1×VEGF space. The agreement, unveiled at the JPMorgan Healthcare Conference, includes additional milestone...
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
Moderna announced a 2025 revenue outlook of $1.9 billion, aligning with the midpoint of its narrowed $1.6‑$2 billion range and matching Wall Street expectations. The biotech also trimmed its operating expense forecast to $5‑$5.2 billion, a $200 million reduction from the prior November guidance....
Combining IVF and Surgery for Endometriosis Fertility Solutions
A new clinical protocol merges in‑vitro fertilization (IVF) with minimally invasive endometriosis surgery to boost fertility outcomes. Early trials show that removing endometriotic lesions before embryo transfer raises live‑birth rates by up to 25 percent compared with IVF alone. The approach...
JPM: AbbVie Pays $650m Upfront for RemeGen Cancer Drug
AbbVie has signed a $5.6 billion licensing agreement with China’s RemeGen, paying $650 million upfront for exclusive rights to the PD‑1×VEGF bispecific antibody RC148 outside Greater China. The deal includes up to $4.95 billion in milestone payments and gives AbbVie access to a...
Mitigating Emissions From Air Freight: Unlocking the Potential of SAF with Book and Claim
Air freight emissions have jumped 25% since 2019, adding roughly 20 million tonnes of CO₂ annually. Sustainable aviation fuel (SAF) can slash lifecycle greenhouse‑gas emissions by up to 80%, and the IATA sees it delivering 65% of the sector’s reductions. High...